HURA
TuHURA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.14
+1.90%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -23.5%
- EBIT
- -25.8%
- EPS
- +84.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -6.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -68.4%
- EBIT
- -80.2%
- Net income
- -38.6%
- EPS
- +47.9%
- Free cash flow
- -87.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026